Successful management of recurrent feline hepatic lipidosis with equine placenta extract supplementation: A case report.

BACKGROUND

Hepatic lipidosis (HL) is a common and life-threatening hepatopathy in cats, for which novel therapeutic options remain limited.

CASE DESCRIPTION: A 14-year-old neutered male Egyptian Mau cat presented with a 1-week history of anorexia, intermittent vomiting, and jaundice. Plasma biochemistry revealed markedly elevated levels of alanine aminotransferase (ALT: 7270 U/L), aspartate aminotransferase (AST: 2754 U/L), and total bilirubin (5.5 mg/dl). Histopathological examination revealed multifocal hepatocellular vacuolar degeneration and random hepatocellular necrosis, consistent with HL, potentially associated with chronic enteropathy and a suspected early neoplastic lymphoid process. Standard therapy with hepatoprotective agents and nutritional support led to limited improvement; therefore, 2 ml of equine placental extract (EPE; Japan Bio Products Co., Ltd., Japan) was administered orally once daily. The cat remained clinically stable with continued administration of EPE and ursodeoxycholic acid.

CONCLUSION

EPE may represent a potential novel adjunctive therapy for feline hepatic lipidosis and was temporally associated with biochemical improvement, indicating hepatocellular recovery and appetite restoration in this case.